ONUREG
Active Ingredient: AZACITIDINE
Product Overview
About ONUREG
ONUREG is a medication that contains the active ingredient AZACITIDINE, which is used for the treatment of certain types of cancer. Specifically, ONUREG is utilized in the management of adult patients with acute myeloid leukemia (AML) who have achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy. The primary goal of ONUREG in this context is to maintain the remission and prevent the recurrence of the disease.
Key Benefits & Uses
- Maintenance therapy for adult patients with AML in first complete remission
- Helps in reducing the risk of disease recurrence
- May improve overall survival in certain patient populations
Active Ingredient & Action
AZACITIDINE, the active ingredient in ONUREG, works by inhibiting DNA methyltransferase, leading to a re-expression of silenced genes, which can help in controlling the growth and proliferation of cancer cells. This mechanism of action is crucial for its effectiveness in treating AML and potentially other myelodysplastic syndromes.
Important Notes
Patients should be advised to follow the prescribed dosage and administration schedule for ONUREG. It is also crucial to monitor for potential side effects and report them to a healthcare provider. ONUREG should only be used under the guidance of a qualified healthcare professional, as it is a potent medication that requires careful management to minimize risks and maximize benefits.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.
